Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited has informed the Exchange about change in Management

Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited has informed the Exchange about Minutes of the 32nd Annual General Meeting held on September 30, 2026.

Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities for the quarter ended September 30, 2026.

Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited has informed the Exchange about the voting results of its 32nd Annual General Meeting held on September 30, 2026. The meeting approved the audited standalone and consolidated financial statements for the financial year ended March 31, 2026, and declared a dividend of Rs. 1.80 per equity share for the financial year 2025-2026. A director, Mr. Hashmukh I. Patel, was also re-appointed.

Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited has held its 32nd Annual General Meeting (AGM) on September 30, 2026, where the company's financial performance for the year ended March 31, 2026, was discussed. The meeting also approved the appointment of directors, dividend declaration, and other ordinary and special businesses.

Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited has informed the Exchange about change in Management

Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited has informed the Exchange about change in Management

Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window will remain closed from October 1, 2026, till 48 hours after the declaration of the Financial Results of the Company for the quarter ended September 30, 2026.

Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication for Notice of 32nd Annual General Meeting.

Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited has informed the Exchange about dispatch of physical communication to shareholders who have not registered their email address. The company is also informing shareholders about the 32nd Annual General Meeting (AGM) and the Annual Report for the Financial Year 2025-26.

Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited has informed the Exchange regarding Notice of 32nd Annual General Meeting to be held on September 30, 2026, to consider and adopt audited financial statements, declare dividend, and re-appoint directors.

Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 11-Sep-2026.

Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication regarding the 32nd Annual General Meeting of the Company to be held on Wednesday, September 30, 2026.

Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited has informed the Exchange about the publication of un-audited financial results for the quarter ended June 30, 2026, in accordance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of ₹3,623.45 lakhs and earnings per share of ₹18.09.

Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing on stock exchanges.

Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.